Merck KGaA Rules Out Major M&A, Says MS Pill Mavenclad Will Be Major Earner
Executive Summary
The German group has been laying out its future plans to investors, which include reducing debt and a strong revenue stream from its Pfizer-partnered checkpoint inhibitor Bavencio.
You may also be interested in...
EU Biosimilar Action: New Competitors For Remicade/Herceptin, Four More Products Await CHMP OK
Two more biosimilar medicines have been approved in the EU: Sandoz’s Zessly (infliximab) and Amgen’s Kanjinti (trastuzumab). Four other biosimilars are expecting a CHMP opinion this week, including three versions of AbbVie's Humira.
Post-Rebif, Merck KGaA Keeps Faith With MS Therapies
CEO Stefan Oschmann is sticking to his previous forecast of annual peak sales of €500-700m for Mavenclad, excluding the US, and Merck has high hopes for another MS treatment, the BTK inhibitor evobrutinib, following promising Phase IIb data.
Celgene Joins Troubled MS Club With Refuse To File For Ozanimod From US FDA
Other multiple sclerosis contenders – including Sanofi's Lemtrada, Acorda's Ampyra, and Merck KgAA's cladribine – have also been RTFed. Question now for Celgene is how long the delay will be.